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Abstract – Macrophage migration inhibitory factor (MIF) is implicated in the pathogenesis of several inflammation-
related diseases, including obesity and type 2 diabetes (T2D). However, MIF deficiency itself promotes obesity and glu-
cose intolerance in mice. Here we show that the introduction of a high-fat diet (HFD) further aggravates the parameters 
of obesity-associated T2D: weight gain and glucose intolerance. Furthermore, in contrast to MIF-KO mice on standard 
chow, HFD-fed MIF-KO mice develop insulin resistance. Although the clinical signs of obesity-associated T2D are 
upgraded, inflammation in MIF-deficient mice on HFD is significantly lower. These results imply that MIF possesses 
a complex role in glucose metabolism and the development of obesity-related T2D. However, the downregulation of 
inflammation upon MIF inhibition could be a useful tool in short-term T2D therapy for preventing pancreatic islet 
deterioration.
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INTRODUCTION
Type 2 diabetes (T2D) is a heterogeneous disease 
characterized by hyperglycemia resulting from the 
progressive development of insulin resistance ac-
companied by defects in insulin secretion (Stumvoll 
et al., 2005). Apart from a genetic predisposition, 
the risk of developing T2D in humans increases 
with age, obesity, cardiovascular disease (hyperten-
sion, dyslipidemia) and a lack of physical activity. A 
sedentary lifestyle combined with energy-rich diets 
leads to obesity, which often precedes the onset of the 
disease. Recent findings describe obesity as a state of 
chronic, low grade inflammation as increased levels 
of inflammatory cytokines (tumor necrosis factor-α 
– TNF-α, interleukin-6 – IL-6, interleukin-1β – IL-
1β) and acute-phase reactants (C-reactive protein 
– CRP, haptoglobin, fibrinogen) are seen in obese 
subjects (Donath and Shoelson, 2011; Lumeng and 
Saltiel, 2011). Furthermore, elevated levels of IL-1β, 
IL-6 and CRP are predictive of T2D (Pascual et al., 
2005; Viardot et al., 2010). These detrimental mol-
ecules are derived from the adipose tissue of the 
obese, but also from the immune cells (Donath and 
Shoelson, 2011).
Macrophage migration inhibitory factor (MIF) 
is a pro-inflammatory cytokine associated with the 
development of many immune diseases, including 
T1D (Cvetkovic et al., 2005; Stosic-Grujicic et al., 
2008), T2D and obesity (Ghanim et al., 2004; Church 
et al., 2005). Macrophages have been identified as a 
primary source of MIF (Calandra et al., 1994). In-
terestingly, human and murine adipocytes are also a 
source of MIF (Hirokawa et al., 1997; Skurk et al., 
2005). MIF is elevated in the serum of patients with 
T2D (Yabunaka et al., 2000), and mononuclear cells 
of the obese demonstrate higher levels of MIF (Dan-
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dona et al., 2004). In addition, MIF can cause dam-
age to pancreatic beta cells in cooperation with high 
levels of nutrients (Saksida et al., 2012). 
We have previously shown an increase in sys-
temic and locally produced MIF in C57BL/6 mouse 
fed a high-fat diet (HFD), which correlated with the 
weight gain and the developed glucose intolerance 
(Saksida et al., 2012). The aim of this study was to 
investigate further the role of MIF in diet-induced 
obesity by feeding mice lacking the Mif gene with a 
high-fat food. Having in mind the inflammatory mi-
lieu of obesity, we measured the serum levels of CRP, 
IL-6 and tumor growth factor-β (TGF-β).
MATERIALS AND METHODS
Material
Unless stated otherwise, all chemicals were pur-
chased from Sigma-Aldrich, St Louis, MO, USA.
Animals
The breeding stock of Mif gene deficient (MIF-KO) 
mice on the C57BL/6 (B6) background was kindly pro-
vided by Dr Yousef Al-Abed (The Feinstein Institute 
for Medical Research, North Shore LIJ Health System, 
New York, USA) and the mice were further bred using 
homozygous MIF-KO animals. MIF-KO mice were 
housed along with their wild type (WT) C57BL/6 
counterparts under standard conditions (non-specific 
pathogen free) in the Animal Facility at the Institute 
for Biological Research “Siniša Stanković”. The experi-
ments were approved by the local Ethical Committee 
(# 12/07) and conducted in accordance with local and 
international legislation regarding the well-being of 
laboratory animals. 
Induction of obesity-associated T2D
C57BL/6 and MIF-KO mice (8 weeks old, 35 mice 
per group) were fed for 16 weeks with either a con-
trol diet (CD – 10% fat, 3.7 kcal/g) or a high-fat diet 
(HFD – 60% fat, 5.1 kcal/g) obtained from Harlan, 
Madison, USA. 
Intraperitoneal insulin (IPITT) and glucose tolerance 
tests (IPGTT)
IPITT was performed by insulin injection (0.8 μg/g 
body weight) to fed mice, while IPGTT was done on 
fasted mice by injection of D-glucose (2 mg/g body 
weight). Blood glucose (from the tail vein) was meas-
ured at specific time points.
Serum analysis
The animals were bled from the orbital plexus and 
the sera were stored at -80°C. The sera were exam-
ined using ELISA kits for insulin (Mercodia, Uppsa-
la, Sweden), CRP (Anogen, Ontario, Canada), leptin 
(R&D, Minneapolis, MN, USA), triglycerides (Wako 
Chemicals, Richmond, VA, USA) and with paired 
antibodies for IL-6 (eBioscience, San Diego, CA, 
USA), and TGF-β (R&D) according to the manufac-
turers’ instructions. 
Statistical analysis
The results from 2-3 experiments were presented as 
means ± SD. To analyze the significance of the differ-
ences between various treatments, analysis of vari-
ance (ANOVA) followed by the Student-Newman-
Keuls test for multiple comparisons, or the Student’s 
t-test were used as appropriate. A p value less than 
0.05 was considered to be significant. The statistical 
package used was Statistica 6.0 (StatSoft Inc., Tulsa, 
OK, USA).
RESULTS
MIF deficiency further promotes obesity in  
HFD-fed mice
By about 15 weeks of age, the weight gain of MIF-KO 
mice on CD became significantly higher compared to 
B6 mice on the same diet (Fig. 1A). The introduction 
of the HFD to 8-week-old MIF-KO mice resulted 
in a more profound difference in body weight after 
9 weeks of feeding compared to the same strain on 
the CD diet. Interestingly, the development of obes-
ity in B6 and MIF-KO on HFD followed a similar 
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pattern until week 14 of the experiment when the 
MIF-KO mice started to gain more weight than the 
B6 mice (Fig. 1A). Both strains on HFD increased 
their triglycerides over time, but triglyceride levels 
in the MIF-KO mice were lower at week 14 (Fig. 1B). 
At the same time point, serum leptin was significant-
ly higher in the MIF-KO mice compared to the B6 
mice (Fig. 1C). Seemingly, both strains on CD had 
normal leptin levels throughout the experiment (not 
shown). 
MIF deletion influences insulin resistance
MIF-KO mice on CD showed slightly higher levels 
of fasting glucose and impaired glucose tolerance 
compared to B6 on the same diet (Fig. 2A, B). HFD 
elevated fasting glycemia and further promoted glu-
cose intolerance in the MIF-KO mice (Fig. 2A, B). 
IPITT resulted in normal glucose disposal in both 
strains on CD (Fig. 2C). However, in the same test 
the MIF-KO mice on HFD were unable to lower the 
serum glucose properly, indicating a marked insulin 
resistance that was greater than the one seen in B6 
on HFD (Fig. 2C). The serum insulin concentration 
remained normal in the mice on CD, but increased 
over time in both strains on HFD (Fig. 2D). 
MIF deletion prevents HFD-induced changes in  
serum inflammatory markers
Obesity is usually associated with the chronic pres-
ence of slightly elevated proinflammatory mediators. 
Notably, serum CRP and IL-6 levels were downreg-
ulated in the HFD-fed MIF-KO mice compared to 
the B6 mice on the same diet (Fig. 3A, B), while the 
TGF-β concentration declined over time in the sera 
of both mouse strains on HFD (Fig. 3C). The levels 
of all mentioned parameters in the CD-fed mice did 
not change throughout the experiment (not shown). 
DISCUSSION
This study shows that the absence of MIF simulta-
neously promotes diet-induced obesity and insulin 
resistance in mice, and abrogates chronic inflamma-
tion.
MIF is implicated in the development of obesity 
and T2D in humans (Ghanim et al., 2004; Church 
et al., 2005) and in B6 mice (Saksida et al., 2012). 
Fig. 1. The effect of MIF deletion on obesity, triglyceride and 
leptin levels. Body weight of B6 and MIF-KO mice on CD and 
HFD was measured weekly (A). Triglycerides from serum of 
non-fasting mice (B). Serum leptin concentration (C). Data are 
presented as mean ± SD, n=15-50, * indicates p<0.05 vs. MIF-KO 
CD, # indicates p<0.05 vs. B6 HFD. 
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Additionally, MIF deficiency protects mice from the 
development of glucose intolerance in atheroscle-
rotic-prone mice (Verschuren et al., 2009) or during 
endotoxemia (Atsumi et al., 2007). However, results 
obtained by Serre-Beinier et al. (2010) suggest that 
MIF-KO mice spontaneously develop obesity and 
glucose intolerance in adult age (12 months old). 
Interestingly, these mice did not develop insulin re-
sistance. Our experiments confirm their findings, 
although our colony of MIF-KO mice developed 
glucose intolerance by the age of 8 weeks, while the 
introduction of HFD exacerbated the parameters of 
obesity and T2D, including the appearance of insulin 
resistance.
The normal serum insulin and insulin tolerance 
seen in CD-fed MIF-KO mice suggests that insulin 
receptor and signaling are fully operative. In addi-
tion, endotoxemic MIF-KO mice display normal 
glucose uptake (Atsumi et al., 2007). Therefore, the 
defect may reside in MIF-KO islets’ capacity for in-
sulin secretion. Indeed, impaired IPGTT confirmed 
that MIF-KO islets might possess an innate defect in 
insulin secretion what is in accordance with in vivo 
studies by Serre-Beinier et al. (2010). The observed 
impairment might stem from MIF’s positive influ-
ence on the insulin secretion pathway (Waeber et al., 
1997). 
Recent data suggest that MIF blood or serum 
levels correlate with leptin levels in obese subjects 
(Sheu et al., 2008; Sumarac-Dumanovic et al., 2009). 
Indeed, the leptin serum was higher in the HFD-fed 
MIF-KO compared to the B6 mice approximately at 
the time when a significant difference in weight gain 
between the two strains was observed. 
Many reports indicate that MIF is actually po-
sitioned at the top of the inflammatory cascade and 
that MIF deficiency benefits almost every condition 
with underlying inflammation processes; but it also 
reduces the ability of cells to produce TNF-α, IL-1, 
Fig. 2. MIF absence provoked glucose intolerance and insulin resistance. Blood was taken from the tail vein of fasting animals on a 
weekly basis and glucose was measured (A).IPGTT was performed on fasting mice at week 7 of the experiment (B). IPITT was per-
formed at week 7 of the experiment (C). Serum insulin concentration (D). Data are presented as mean±SD, n=10-15, * indicates p<0.05 
vs. MIF-KO CD, # indicates p<0.05 vs. B6 HFD.
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IL-6, IL-17, IL-23 (Cvetkovic and Stosic-Grujicic, 
2006; Stosic-Grujicic et al., 2009). More specifical-
ly, it has been shown that MIF absence reduces the 
chronic inflammation associated with obesity and 
atherosclerotic disease (Verschuren et al., 2009). 
Similarly, our results suggest that the reason for the 
downregulation of inflammation in HFD-fed MIF-
KO mice could be MIF deficiency itself. However, 
HFD resulted in a significant drop of serum TGF-β 
over time in both strains, indicating that MIF defi-
ciency affected only the pro-inflammatory arm of the 
immune response.
One of MIF’s functions is the counter-regulation 
of glucocorticoid immunosuppressive action. Apart 
from interfering with immune response, the excess of 
glucocorticoids affects insulin signaling and inhibits 
glucose-stimulated insulin release in vitro (Lambil-
lotte et al., 1997; Staab and Maser, 2010). Therefore, 
in the absence of MIF, glucocorticoids lack their nat-
ural opponent and the observed defects in islet in-
sulin secretion and the suppression of inflammation 
could be consequences of elevated glucocorticoids.
CONCLUSION
This study suggests that the role of MIF in obesity 
and T2D is complex. On one side, MIF is clearly 
important for retaining the normal function of beta 
cells, while on the other, MIF acts as a booster of the 
inflammation that underlines T2D development. 
Also, having in mind that MIF in a nutrient-rich 
environment can induce beta cell apoptosis, therapy 
with MIF blockers at specific time points during T2D 
pathogenesis may prolong the time without exog-
enous insulin treatment. Therefore, research focused 
on the determination of the exact time for anti-MIF 
therapy during HFD-induced obesity-associated 
T2D is warranted. 
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